High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma

Clinical and Experimental Metastasis

Volumn 17, Issue 10, 1999, Pages 799-808

  Davidson, Ben ^a,b   Goldberg, Iris ^c,d   Gotlieb, Walter H ^c,d   Kopolovic, Juri ^c,d   Ben Baruch, Gilad ^c,d   Nesland, Jahn M ^a,b   Berner, Aasmund ^a,b   Bryne, Magne ^a,b   Reich, Reuven ^e,f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Disease outcome; MMP 2; MMP 9; MRNA in situ hybridization; MT1 MMP; Ovarian carcinoma

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION FUNCTION; ENZYME ANALYSIS; FEMALE; HUMAN; IN SITU HYBRIDIZATION; OUTCOMES RESEARCH; OVARY CARCINOMA; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RNA ANALYSIS; STATISTICAL ANALYSIS;

ADULT; AGED; CARCINOMA; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0033762457     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006723011835     Document Type: Article

References (55)

1. Tumor invasion and the extracellular matrix
2. ECM and cell surface proteolysis: Regulating cellular ecology
3. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression
4. Molecular aspects of tumor cell invasion and metastasis
5. The matrix-degrading metalloproteinases
6. Tumor invasion and metastasis: An imbalance of positive and negative regulation
7. Type IV collagenases in invasive tumors
8. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis
9. Matrix metalloproteinases and their inhibitors in connective tissue remodeling
10. Changing views of the role of matrix metalloproteinases in metastasis
11. Cancer statistics, 1996
12. Prospective on ovarian cancer: Why prevent?
13. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion
14. Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa Gelatinase A (MMP-2)
15. Collagenase expression in ovarian cancer cell lines
16. MMP-2 release and activation in ovarian carcinoma: The role of fibroblasts
17. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies
18. Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues
19. MT1-MMP and MMP-2 mRNA expression in human ovarian minors. Possible implications for the role of desmoplastic fibroblasts
20. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines
21. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells
22. Characterization of Gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2
23. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells
24. Expression and activity of MMPS and their regulators in ovarian cancer
25. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary
26. Expression of 72 kilodalton type IV collagenase (Gelatinase A) in benign and malignant ovarian tumors
27. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma
28. 72-KiloDalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors of the ovary: A clinicopathologic, immunohistochemical, and serological study
29. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: Clinical and prognostic implications
30. Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer
31. Ovarian neoplasms
32. Automated molecular pathology: One-hour in-situ DNA hybridization
33. Complete one-hour immunocytochemistry based on capillary action
34. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique
35. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma- A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
36. Matrix metalloproteinases and metastasis
37. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
38. Promising new developments in cancer chemotherapy
39. Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma
40. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
41. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization
42. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma
43. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: Clinico-pathological correlations
44. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
45. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma
46. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis
47. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
48. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer
49. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer
50. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina
51. High levels of tissue inhibitor of metalloproterinase-2 (TIMP-2) are associated with poor outcome in invasive bladder cancer
52. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen
53. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin